Dermisonics, Inc.
Dermisonics, Inc.: Test With Type 2 Diabetics Proves Ultrasound Component Of The U-Strip System Does Not Damage The Skin
Corporate news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Dermisonics’ Test With Type 2 Diabetics Proves Ultrasound Component Of The
U-Strip System Does Not Damage The Skin
Represents major step forward in achieving FDA approval
Irvine, CA — September 19, 2006, Dermisonics, Inc. (OTCBB: DMSI; FWB:
FQC), a developer of painless injection-free ultrasonic transdermal
drug-delivery patches and technologies with broad pharmaceutical and
consumer applications, announced today that it successfully completed its
HPT-4 human pilot trial of its proprietary U-Strip transdermal
drug-delivery system in patients with Type-2 diabetes.
Goal of Study – This trial specifically examined the effects of the unique
ultrasonic transmission utilized in the U-Strip insulin delivery system
upon the skin of type-2 diabetic patients. The goal of this study was to
demonstrate that ultrasound alone, at levels used for ultrasonic drug
delivery, does not cause skin damage or irritation.
Study Design – The study was conducted upon 25 adult Type-2 diabetic
patients of both sexes, with an average time on disease of at least 10
years. A blank transdermal patch (without insulin) was fitted on the left
upper arm and the right side of the abdomen of each volunteer. The
volunteers were tested over a five-hour test period, where ultrasound was
applied continuously. The duration of the application of the ultrasound
during the test period is greater than what is proposed for the application
of insulin applied by U-Strip system. The U-Strip system produces an
ultrasonic signal that is less than 1/5 the power of a ultrasonic
toothbrush. The completed trial revealed no adverse skin reactions, no skin
irritation or skin damage among any of the volunteers.
Results – The trial revealed no adverse skin reactions, no skin irritation
or skin damage among any of the volunteers. In a word, this study
demonstrates that the ultrasound component of the U-Strip system does not
damage the skin, even the skin of highly sensitive Type-2 diabetics.
Currently, people with diabetes rely on regular, frequent needle injections
of insulin to control blood glucose levels. Dermisonics’ proprietary
U-Strip system employs proprietary microelectronics and ultrasonic
technologies with a drug-carrying patch to enable the painless delivery of
large-molecule drugs through the skin’s natural pores and hair follicles.
Continuing Studies – The Company is continuing its two other
investigational review board (approved human pilot trials (HPT-2 and HPT-3)
to further demonstrate the efficacy of the U-Strip system. HPT-3 is
designed to demonstrate that wearing the insulin patch will not damage the
skin of the patient; HPT-2 is designed to demonstrate the ability of the
U-Strip System the to deliver controlled doses of insulin to patients,
comparing the rate of delivery of insulin in comparison to an insulin pump.
The Company anticipates announcing the results of HPT-3 before the end of
September 2006. The Company anticipated completion of HPT 2 by the end of
2006.
About Dermisonics, Inc. – Dermisonics is an intellectual property company
and advanced technology incubator that is primarily focused on the ongoing
development, testing and eventual commercialization of a transdermal patch
that has been designed to facilitate the efficient and needle-free delivery
of drugs with large molecular structures into the bloodstream. Its
breakthrough system, called the U-Strip, is based on a radical integration
of microelectronics and ultrasonic science with a product-carrying patch,
and represents a quantum leap in non-invasive, transdermal delivery
technology. Company tests have shown that this system facilitates the
transdermal delivery of insulin and has the potential to deliver at least
175 other existing drugs that at present cannot be effectively delivered
through the pores of the skin using conventionally available transdermal
technology due to their large molecular size. For more information visit
http://www.Dermisonics.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although the
Company believes that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are reasonable, it
can give no assurance that such expectations and assumptions will prove to
have been correct. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to
numerous factors and uncertainties, including but not limited to adverse
economic conditions, intense competition, lack of meaningful research
results, entry of new competitors and products, adverse federal, state and
local government regulation, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, technological obsolescence of the
Company’s products, technical problems with the Company’s research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible acquisition
of new businesses or that result in operating losses or that do not
perform as anticipated, unanticipated losses, the possible fluctuation and
volatility of the Company’s operating results, financial condition and
stock price, losses incurred in litigating and settling cases, dilution in
the Company’s ownership of its business, adverse publicity and news
coverage, inability to carry out research, development and
commercialization plans, loss of key executives and research scientists,
changes in interest rates, inflationary factors, and other specific risks.
In addition, other factors that could cause actual results to differ
materially are discussed in the Company’s most recent Form 10-QSB and Form
10-KSB filings with the Securities and Exchange Commission.
Contacts:
Dermisonics, Inc.
Bruce.Haglund@dermisonics.com
Raymond.Peterson@dermisonics.com
888-401-DERM (3376) Toll Free
Investor Relations Contacts:
International Market Trend
Toll-Free North America
1-877-676-4447
Michael Drepper
Phone: +49-621-430-6130
investor-germany@dermisonics.com
(c)DGAP 20.09.2006
—————————————————————————
Language: English
Issuer: Dermisonics, Inc.
Dermisonics, Inc.
19428-2977 West Conshohocken, Pa. Vereinigte Staaten von Amerika
Phone: +1 610-941-2780
Fax: +1 610-941-2990
E-mail: bruce.haglund@dermisonics.com
WWW: dermisonics.com
ISIN: US24983U1043
WKN: A0DK4Y
Indices:
Listed: Freiverkehr in Berlin-Bremen; Open Market in Frankfurt
End of News DGAP News-Service
—————————————————————————
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden